Atossa Genetics Stock Analysis

ATOS Stock  USD 0.85  0.01  1.08%   
Atossa Genetics is undervalued with Real Value of 2.01 and Target Price of 5.63. The main objective of Atossa Genetics stock analysis is to determine its intrinsic value, which is an estimate of what Atossa Genetics is worth, separate from its market price. There are two main types of Atossa Genetics' stock analysis: fundamental analysis and technical analysis.
The Atossa Genetics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Atossa Genetics is usually not traded on National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Atossa Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Atossa Stock please use our How to Invest in Atossa Genetics guide.

Atossa Stock Analysis Notes

About 27.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atossa Genetics recorded a loss per share of 0.2. The entity last dividend was issued on the 20th of April 2018. The firm had 1:12 split on the 20th of April 2018. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. For more info on Atossa Genetics please contact FCAP MD at 206-588-0256 or go to https://www.atossatherapeutics.com.

Atossa Genetics Investment Alerts

Atossa Genetics is way too risky over 90 days horizon
Atossa Genetics has some characteristics of a very speculative penny stock
Atossa Genetics appears to be risky and price may revert if volatility continues
Net Loss for the year was (25.5 M) with profit before overhead, payroll, taxes, and interest of 0.
Atossa Genetics currently holds about 125.54 M in cash with (21.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Atossa Genetics has a very weak financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Atos successfully supported UEFA Under21 Championship 2025

Atossa Genetics Upcoming and Recent Events

27th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Atossa Largest EPS Surprises

Earnings surprises can significantly impact Atossa Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-12
2024-06-30-0.06-0.050.0116 
2023-05-15
2023-03-31-0.06-0.050.0116 
2022-08-08
2022-06-30-0.06-0.050.0116 
View All Earnings Estimates

Atossa Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Morgan Stanley - Brokerage Accounts2025-03-31
284.2 K
Connor Clark & Lunn Inv Mgmt Ltd2025-03-31
189.3 K
Goldman Sachs Group Inc2025-03-31
187.9 K
Nuveen Asset Management, Llc2024-12-31
170.7 K
Nuveen, Llc2025-03-31
170.7 K
Rhumbline Advisers2025-03-31
129.9 K
Barclays Plc2025-03-31
128.6 K
Jpmorgan Chase & Co2025-03-31
118.9 K
Qube Research & Technologies2025-03-31
91 K
Blackrock Inc2025-03-31
9.6 M
Vanguard Group Inc2025-03-31
6.6 M
Note, although Atossa Genetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Atossa Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 108.13 M.

Management Efficiency

Atossa Genetics has return on total asset (ROA) of (0.2167) % which means that it has lost $0.2167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3487) %, meaning that it created substantial loss on money invested by shareholders. Atossa Genetics' management efficiency ratios could be used to measure how well Atossa Genetics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Atossa Genetics' Non Currrent Assets Other are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 78.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 1.9 M in 2025.
The management team at Atossa Genetics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta
0.9
Return On Assets
(0.22)
Return On Equity
(0.35)

Technical Drivers

As of the 3rd of July, Atossa Genetics shows the Mean Deviation of 3.99, risk adjusted performance of 0.1347, and Downside Deviation of 4.41. Atossa Genetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atossa Genetics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Atossa Genetics is priced correctly, providing market reflects its regular price of 0.84909999 per share. Given that Atossa Genetics is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Atossa Genetics Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Atossa Genetics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Atossa Genetics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Atossa Genetics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atossa Genetics Outstanding Bonds

Atossa Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atossa Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atossa bonds can be classified according to their maturity, which is the date when Atossa Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Atossa Genetics Predictive Daily Indicators

Atossa Genetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atossa Genetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Atossa Genetics Forecast Models

Atossa Genetics' time-series forecasting models are one of many Atossa Genetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atossa Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Atossa Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Atossa Genetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atossa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Atossa Genetics. By using and applying Atossa Stock analysis, traders can create a robust methodology for identifying Atossa entry and exit points for their positions.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.

Current Atossa Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atossa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atossa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.63Strong Buy4Odds
Atossa Genetics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Atossa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atossa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atossa Genetics, talking to its executives and customers, or listening to Atossa conference calls.
Atossa Analyst Advice Details

Atossa Stock Analysis Indicators

Atossa Genetics stock analysis indicators help investors evaluate how Atossa Genetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atossa Genetics shares will generate the highest return on investment. By understating and applying Atossa Genetics stock analysis, traders can identify Atossa Genetics position entry and exit signals to maximize returns.
Begin Period Cash Flow88.6 M
Total Stockholder Equity71.5 M
Cash And Short Term Investments71.1 M
Net Invested Capital71.5 M
Shares Float129.1 M
Cash71.1 M
200 Day M A1.0053
50 Day M A0.8416
Net Interest IncomeM
Total Current LiabilitiesM
Investments-19 K
Stock Based Compensation2.3 M
Common Stock Shares Outstanding125.9 M
Free Cash Flow-21 M
Operating Income-27.6 M
Other Current Assets3.4 M
Accounts Payable679 K
Net Debt-71.1 M
Depreciation17 K
Other Operating Expenses27.6 M
Non Current Assets TotalM
Liabilities And Stockholders Equity76.4 M
Home CategoryDomestic
Non Currrent Assets OtherM

Additional Tools for Atossa Stock Analysis

When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.